Stockscreener 앱 받기
29.58
2.92%
-1.02
전일 마감가:
$30.60
열려 있는:
$30.55
하루 거래량:
71,605
Relative Volume:
0.06
시가총액:
$3.47B
수익:
$22.57M
순이익/손실:
$-212.73M
주가수익비율:
-16.39
EPS:
-1.8045
순현금흐름:
$-142.19M
1주 성능:
-2.22%
1개월 성능:
-16.18%
6개월 성능:
-13.19%
1년 성능:
+50.41%
1일 변동 폭
$29.63
$31.55
1주일 범위
$29.13
$31.55
52주 변동 폭
$17.63
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
29.64 | 3.58B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
450.65 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.75 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.14 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.91 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.41 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma Warrants (NAMSW) Plunge 11.78% as Sellers Dominate, Testing Key SupportVolume Weighted Price - newsline.com
NewAmsterdam Pharma Rises 3.17% as Shares Approach Resistance at $31.77Bollinger Band - newsline.com
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness - Yahoo Finance
(NAMSW) Risk Channels and Responsive Allocation - Stock Traders Daily
NewAmsterdam Pharma Company N.V.Ordinary Shares (NQ: NAMS - FinancialContent
EBIT of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026 - Insider Monkey
All eyes on NewAmsterdam Pharma earnings as pipeline advances - Investing.com
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
Capital World Investors holds 10.4% of NewAmsterdam Pharma (NAMS) - Stock Titan
5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller - Insider Monkey
NewAmsterdam Shareholders Approve ESPP and Governance Proposals - TipRanks
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions - The Manila Times
Oral cholesterol drug obicetrapib in multiple 2026 lipid meeting studies - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) shareholders back 2026 ESPP and extend share issuance powers - Stock Titan
(NAMSW) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Debt to assets ratio of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Inventory turnover of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
EBIT per share of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Current ratio of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Net income before discontinued operations of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Taxes of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - Sahm
NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus - Bez Kabli
NewAmsterdam Pharma (NAMS) CAO exercises options and sells 65,000 shares - Stock Titan
NewAmsterdam Pharma Warrants (NAMSW) Rally 3.05% as Price Nears Key ResistanceOvervalued Signals - thelegaladvocate.com
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
NewAmsterdam Pharma (NAMS) Edges Higher as Shares Test Key Resistance LevelArms Index - The Legal Advocate
Technical Reactions to NAMS Trends in Macro Strategies - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Q1 2026 Earnings: EPS Beat Reflects Cost Management Amid Pre-Revenue Phase - The Legal Advocate
NewAmsterdam Pharma Co NV (HAM:KH6) Cyclically Adjusted Pri - GuruFocus
NewAmsterdam Pharma (NAMS) Slightly Lower Amid Consolidation Near Key Support LevelsGamma Squeeze - newsline.com
NewAmsterdam Pharma Insiders Who Sold Avert US$477m Market Cap Dip - Moomoo
Bain Life Sciences trims NewAmsterdam (NAMS) holding to about 3.3% - Stock Titan
Trading the Move, Not the Narrative: (NAMS) Edition - Stock Traders Daily
Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts - Sahm
NewAmsterdam Pharma Company N.V. (NAMS) Eps Diluted (TTM) - Zacks Investment Research
NAMS: Interim PREVAIL results expected Q1 next year, with strong efficacy and broad market potential - TradingView
Piper Sandler reiterates NewAmsterdam Pharma stock rating at overweight By Investing.com - Investing.com Nigeria
TradingKey - TradingKey
Piper Sandler reiterates NewAmsterdam Pharma stock rating at overweight - Investing.com
HC Wainwright Has Negative Forecast for NAMS Q2 Earnings - MarketBeat
NewAmsterdam Pharma stock hits all-time high at 42.02 USD By Investing.com - Investing.com India
NAMS SEC FilingsNewAmsterdam Pharma Company N.V 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL TrialSlideshow (NASDAQ:NAMS) 2026-05-11 - Seeking Alpha
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Why NewAmsterdam Pharma (NAMS) Is Up 29.7% After Detailing Obicetrapib Phase 3 And Launch Milestones - simplywall.st
NewAmsterdam Pharma stock hits all-time high at 42.02 USD - Investing.com
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.61%
자본화:
|
볼륨(24시간):